Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAPEST: Erlotinib and Sulindac for Duodenal Adenomas in FAP
NCT01187901Phase 2Completed
- Sponsor
- University of Utah
- Start
- Apr 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, sulindac in familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), sponsored by University of Utah. Started Apr 2010; status: completed.
02
Drugs
erlotinibsulindac
03
Conditions
familial adenomatous polyposis (FAP)attenuated familial adenomatous polyposis (AFAP)
Beyond the preview
Go deeper on NCT01187901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01187901.